Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R
Long-term treatment with adefovir dipivoxil is more cost-effective than lamivudine for HBeAg-negative patients with chronic hepatitis B
56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, California, EEUU. 11-15 nov 2005
Casado MA
The pharmacoeconomics of anti-HBV treatments. Monothematic conference: From viral pathobiology to the treatment of hepatitis B virus infection
Istanbul, Turkey. 6-8 oct 2005
Casado MA, Ventura JM
Impacto en el presupuesto hospitalario de los interferones pegilados en el tratamiento de los pacientes con hepatitis crónica C
50 Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria (SEFH). Oviedo, España. 27-30 sep 2005
Wong JB, Buti M, Casado MA, Fosbrook L, Soriano V, Esteban R
Cost-effectiveness of peginterferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-HCV co-infected patients
40th Annual Meeting of the European Association for the Study of the Liver (EASL). Paris, France. 13-17 apr 2005
Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R
Cost-effectiveness of two oral antiviral therapies, lamivudine and adefovir dipivoxil of HBeAg-negative chronic hepatitis B
40th Annual Meeting of the European Association for the Study of the Liver (EASL). Paris, France. 13-17 apr 2005
Buti M, Wong J, Casado MA, Esteban R
Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. Co-infected Patients
1st European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV. Paris, France. 1-2 mar 2005
Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R
Análisis coste-efectividad de dos tratamientos antivirales de administración oral, lamivudina y adefovir dipivoxil, en pacientes HBeAg negativos con hepatopatía compensada
XXX Congreso Nacional de la Asociación Española para el Estudio del Hígado (AEEH). Madrid, España. 17-19 feb 2005
Buti M, Casado MA, Fosbrook L, Esteban R
Financial impact of two different ways of evaluating early virological response to peginterferon alfa-2b plus ribavirin therapy in genotype 1 naïve patients with chronic hepatitis C
Pharmacoeconomics. 2005;23:1043-55
Buti M, Sanmiguel R, Brosa M, Cabasés JM, Medina, M, Casado MA, Fosbrook L, Esteban R